

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/165591 A1

(51) International Patent Classification:

C07D 498/22 (2006.01) A61K 31/4188 (2006.01)
A61P 31/00 (2006.01) C07D 519/00 (2006.01)

(21) International Application Number:

PCT/EP2024/052975

(22) International Filing Date:

07 February 2024 (07.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23156170.5 10 February 2023 (10.02.2023) EP

(71) Applicant: **BIOVERSYS AG** [CH/CH]; Hochberger-
strasse 60c, 4057 Basel (CH).

(72) Inventors: **ANTRAYGUES, Kevin**; 306 rue Jules Vallès,
59120 Loos (FR). **BOUROTTE, Marilyne**; 74 Avenue du
Kemmel, 59840 Perenchies (FR). **DALE, Glenn E.**; C.F.
Meyer-Strasse 10, 4053 Basel (CH). **DEFERT, Olivier**;
1 Bd JB Lebas, 59000 Lille (FR). **DRENEAU, Aurore**;
237 rue Saint Sébastien, 59800 Lille (FR). **GITZINGER,
Marc**; c/o BioVersys AG Hochbergerstrasse 60c, 4057
Basel (CH). **LOCIURO, Sergio**; Fasanenstrasse 121, 4058
Basel (CH). **MAINGOT, Mathieu**; 2 rue de la Rapine,
59800 Lille (FR). **MICHELOTTI, Alessia**; 38 rue d'Al-
ger, 59110 La Madeleine (FR). **TREBOSC, Vincent**; 5 im-
passe de l'écluse, 68680 Kembs (FR). **WILLAND, Nico-
las**; 8 rue de la Halle, 59800 Lille (FR). **KHAN, Nawaz**; c/
o BioVersys AG Hochbergerstrasse 60c, 4057 Basel (CH).
HOFMANN, Line; c/o BioVersys SAS 1 rue du Professeur
Calmette, 59800 Lille (FR). **MILJKOVIC, Marija**; c/o
BioVersys AG Hochbergerstrasse 60c, 4057 Basel (CH).

(74) Agent: **SPERRLE, Martin**; Latscha Schöllhorn Partner
AG Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: RIFABUTIN ANALOGS FOR THE TREATMENT OF BACTERIAL DISEASES

(57) Abstract: The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is caused by one or more bacterium belonging to a genus of non-tuberculous *Mycobacteria*, preferably *M. abscessus*.

WO 2024/165591 A1